HKUMed-Tsinghua research team (IMAGE)

The University of Hong Kong

HKUMed-Tsinghua research team

Caption

HKUMed-Tsinghua research team has developed MB-32, a first-in-class broad-spectrum small-molecule antiviral drug candidate, which effectively blocks infection by SARS-CoV-2 and its variants. The research is led by (from left, back row) Professor Chen Zhiwei, Professor Chu Hin and (middle front) Dr Liu Li.

Credit

The University of Hong Kong

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.